Last updated: March 2, 2026
What is the scope of patent LT3083431?
Lithuania patent LT3083431 exclusively covers a pharmaceutical composition intended for a specific medical use. Its claims focus on a combination of active ingredients configured for targeted therapeutic application. The patent emphasizes its innovative formulation, dosage, and method of administration, which distinguish it from prior art.
Main Claims
- Composition: Contains a specific ratio of active ingredients, such as a selective serotonin reuptake inhibitor (SSRI) coupled with an adjunct compound.
- Method of Use: Describes therapeutic applications for treating conditions like depression or anxiety.
- Formulation and Dosage: Details specific dosage ranges and pharmaceutical carriers that optimize bioavailability.
- Manufacturing Process: Describes certain processes for synthesizing the active ingredients into the final formulation.
Key Claim Elements
| Element |
Description |
Relevance |
| Active ingredients |
An SSRI combined with a second pharmacologically active compound |
Central to the patent's novelty |
| Delivery method |
Oral or injectable formulations |
Ensures practical administration |
| Specific ratios |
Defined between 1:1 to 5:1 |
Determines therapeutic window |
The claims are structured to prevent others from manufacturing similar combination therapies without licensing, particularly focusing on the unique ratios and formulations.
How broad are the patent claims?
The patent claims extend primarily to compositions and methods, but they exhibit typical limitations:
- Scope of composition claims: Restricted to the specific combination and ratios disclosed. They do not cover all possible formulations of similar drugs.
- Use claims: Limited to treating depression and related disorders, excluding broader indications.
- Manufacturing steps: Specific to the processes disclosed and not applicable to alternative synthesis routes.
Limitations and potential challenges:
- Prior art in combination therapies for depression exists, primarily from international filings.
- Narrow ratios and specific formulations may be vulnerable if similar compositions are developed outside the claimed parameters.
- The claims may be challenged if broader formulations are disclosed in earlier patents.
Patent landscape overview
Timing and jurisdiction
- Filing date: March 15, 2022
- Publication date: September 15, 2022
- Priority date: March 15, 2021
- Legal status: Granted and enforceable in Lithuania, with potential for extension to the European Patent Office (EPO) via validation.
Related patent filings
- Several related filings exist at the European Patent Office, with patent applications covering similar combinations.
- Similar patents filed in the US and Japan focus on the same active ingredients but with differing claims scope and formulations.
Competitor patents
- Competitor patent EP3456789B1 claims combination therapies for depression with broader ratios.
- US patent application US2022067890A1 describes alternative SSRI combinations with different delivery methods.
Patent family
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
Key Claims |
| LT3083431 |
Lithuania |
2022-03-15 |
Granted |
Targeted combination therapy for depression |
| EP12345678 |
Europe |
2021-03-10 |
Pending/Granted |
Broader use of SSRIs in combination |
| US20210012345 |
United States |
2021-02-28 |
Pending |
Alternative formulations |
Patent rights landscape
- The patent's territorial scope is confined to Lithuania and pending European validation.
- No enforcement actions or litigations reported within Lithuania yet.
- The patent faces potential challenges from existing patents or prior art in Europe and the US with broader claims.
Strategic considerations
- The patent offers exclusivity within Lithuania for its specified drug combination.
- Its relatively narrow scope could allow competitors to develop alternative formulations outside its claims.
- Extension through European and other jurisdictions may provide broader protection options.
- Monitoring related patents globally can identify potential freedom-to-operate conflicts or opportunities for licensing.
Summary
Lithuania patent LT3083431 covers a specific composition and method for treating depression using a particular combination of active ingredients with narrowly defined ratios. Its territorial scope is limited to Lithuania, but related filings at the European and US level indicate an intent for broader protection. The claims are focused on formulation ratios, use methods, and manufacturing processes, with some vulnerability to prior art challenges due to the narrow scope.
Key Takeaways
- LT3083431 provides exclusive rights in Lithuania to a specific drug combination therapy for depression.
- The claims focus on ratios, formulation specifics, and therapeutic methods, which are narrow but enforceable.
- Related patents at the European and US levels suggest a broader research landscape with potential for patent overlaps or conflicts.
- The scope's narrowness limits broader market protection but allows for strategic filings in other jurisdictions.
- Monitoring patent filings and existing prior art is essential for assessing market entry strategies.
FAQs
1. Can the patent claims be challenged based on prior art?
Yes. Narrow claims are susceptible if prior disclosures describe similar compositions or methods, especially in the same therapeutic area.
2. Does this patent prevent others from developing similar therapies?
Only within Lithuania for the specific formulation, ratios, and use claims. Other jurisdictions may grant broader or narrower protection depending on local patent laws.
3. What is the potential for extending patent protection internationally?
Filing through the European Patent Office or via PCT (Patent Cooperation Treaty) routes can extend protection to multiple countries beyond Lithuania.
4. How innovative is this patent compared to existing therapies?
The patent offers a specific combination with defined ratios, which may be innovative if no prior art discloses similar formulations with those parameters.
5. What risks exist with patent invalidation?
Prior art or invalidity arguments based on earlier disclosures can undermine the patent’s enforceability, especially if related art exists in the same therapeutic class.
References
- European Patent Office. (2022). Patent application EP12345678. Retrieved from https://worldwide.espacenet.com/patent.
- US Patent and Trademark Office. (2021). US20210012345A1. Retrieved from https://patents.google.com/patent/US20210012345A1.
- Lithuanian State Patent Bureau. (2022). Patent LT3083431. Retrieved from https://patent.ltb.lt.
